Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer

NCT00325598 | Completed Phase 1 Results DMC FDA Device

• 1 other identifier: 05-1053 / 201103235
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study investigates the feasibility and safety of delivering radiation therapy only to part of the breast, (the tumor bed and selected areas) rather than the whole breast, for patients with early stage breast cancer.

Conditions

Breast Neoplasms

Outcome Measures

Primary Outcomes (2)

• Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan

  -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her.

  Within 1 year of protocol registration

• Feasibility of PBI Directed External Radiotherapy as Measured by Development of Histological Fat Necrosis or Other Grade 4 Skin or Grade 4 Subcutaneous Toxicity, or Requires Surgery for the Skin/Subcutaneous Toxicity

  -The study will be deemed infeasible if more than 4 patients develop histological fat necrosis or other grade 4 skin or grade 4 subcutaneous toxicity, or requires surgery for her skin or subcutaneous toxicity

  Within 1 year of protocol registration

Secondary Outcomes (7)

• Incidence and Severity of Cutaneous Toxicity

  Up to 5 years

• Incidence of Breast Fibrosis

  Up to 5 years

• Incidence of Fat Necrosis

  Up to 5 years

• Cosmetic Outcome

  Up to 5 years

• Local Control Rate

  Up to 5 years

Study Arms (2)

Cohort 1 (36 Gy)

EXPERIMENTAL

36 Gy in 9 fractions BID x 4 1/2 treatment days

Radiation: Partial Breast Irradiation (PBI)

Cohort 2 (40 Gy)

EXPERIMENTAL

40 Gy in 10 fractions BID over 5 treatment days

Radiation: Partial Breast Irradiation (PBI)

Interventions

Partial Breast Irradiation (PBI) RADIATION

Cohort 1 (36 Gy); Cohort 2 (40 Gy)

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologic Documentation:
• Patients will have histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer.
• Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.
• Tubular, mucinous and medullary variant histologies of infiltrating ductal carcinoma are permitted.
• Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.
• Women age 70 years or older with T1 invasive ductal carcinoma which are estrogen-receptor positive (ER+) with clinically negative axillary nodes who do not undergo surgical lymph node evaluation are also eligible if patient will take hormonal therapy.
• Patients with T1N0 (i+) tumors on sentinel lymph node mapping or dissection (i.e. is tumor deposit is 0.2mm or less, regardless of whether the deposit is detected by IHC or H\&E staining) will also be eligible, provided that completion axillary dissection has been performed to confirm N0 status.
• In the case where invasive cancer is present, the invasive cancer's pathology will be used regardless if DCIS is also present.
• Prior Treatment: Patient may have been treated with adjuvant chemotherapy. Patients may be on adjuvant hormonal therapy or begin hormonal therapy following XRT at the discretion of the medical oncologist.
• Radiation therapy should begin within:
• weeks from definitive surgical procedure
• weeks after chemotherapy, if chemotherapy given first
• Radiation cannot be delivered concurrently with chemotherapy.
• Age \>= 18 years of age
• ECOG Performance Status 0-2.

You may not qualify if:

• The following guidelines are to assist physicians in selecting patients for whom protocol therapy is safe and appropriate. Physicians should recognize that the following may seriously increase the risk to the patient entering this protocol. Patients who meet the following criteria should not be entered in this study:
• a Multicentric IDC of the breast defined as discontiguous tumors separated by at least 5 cm of uninvolved tissue; alternatively, discontiguous tumors that are clinically or mammographically within separate breast quadrants or subareolar central region.
• b Multifocal IDC of the breast, defined as discontiguous discrete foci of invasive carcinoma, separated by uninvolved intervening tissue, but within an overall span of 5cm, or within the same breast quadrant or subareolar central region.
• Tumor \> 2.0 cm, nodal involvement on H\&E staining, or metastatic involvement
• Histological evidence of:
• Lymphovascular invasion: as defined by a tumor embolus present in an endothelial-lined space; cases with tumor emboli present in a space not lined by endothelial cells but otherwise very suspicious for an angiolymphatic space were also considered ineligible.
• EIC (Extensive Intraductal Component): defined as the presence of intraductal carcinoma both within the primary infiltrating ductal tumor (comprising at least 25% of the tumor area) and intraductal carcinoma present clearly beyond the edges of the invasive tumor, or as a predominantly intraductal tumor with one or more areas of focal invasion 7, 55.
• Invasive Lobular Carcinoma
• Infiltrating carcinoma with mixed ductal and lobular features: cases with ambiguous or mixed histologic features that showed positive E-cadherin staining throughout the tumor by immunohistochemistry were classified as ductal type and considered eligible 56, 57.
• Infiltrating papillary carcinoma
• Margins: In-situ or invasive carcinoma present less than 2 mm from the inked resection margin.
• History of cosmetic or reconstructive breast surgery
• Psychiatric illness which would prevent the patient from giving informed consent. Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or connective tissue diseases (lupus, systemic sclerosis or other collagen vascular diseases) which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
• Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 5% risk of relapse within three years.
• Patients with diffuse (\> 1 quadrant or \> 5cm) suspicious microcalcifications

Sponsors & Collaborators

• Washington University School of Medicine: lead

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Imran Zoberi, M.D.
• Organization: Washington University School of Medicine

izoberi@radonc.wustl.edu

314-362-8525

Study Officials

• Imran Zoberi, M.D.

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2006
• First Posted: May 15, 2006
• Study Start: February 14, 2006
• Primary Completion: April 16, 2013
• Study Completion: April 16, 2017
• Last Updated: June 6, 2018
• Results First Posted: November 7, 2016

Record last verified: 2018-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)